Carteolol Hydrochloride

Pharmacological action: 1. Carteolol hydrochloride is a non-selective β-adrenergic receptor blocker that blocks both β1 and β2 receptors. Carteolol hydrochloride has little or no local anesthetic effect. 2. The main difference between carteolol and other β-receptor blockers is that it has intrinsic sympathomimetic activity. 3. This product is carteolol hydrochloride eye drops, which has an intraocular hypotensive effect on patients with high and normal intraocular pressure, and can reduce intraocular pressure by 22-25%. 4. The main metabolite of carteolol, 8-hydroxy-carteolol, is an ocular β-receptor blocker that also has an intraocular hypotensive effect, which may be related to the longer duration of carteolol's intraocular hypotensive effect. 5. The intraocular hypotensive mechanism of this product is mainly to reduce the production of aqueous humor. This product has an effect on the outflow of aqueous humor through the uveal sclera, the ease of aqueous humor outflow and the sclera.

It has a good effect of reducing intraocular pressure in primary open-angle glaucoma. For some secondary glaucoma, ocular hypertension, closed-angle glaucoma that is not completely controlled after surgery, and other glaucoma that is ineffective with other drugs and surgery, the addition of this product to the eye drops can further enhance the effect of reducing intraocular pressure.

Eye drops, 2 times a day, 1 drop each time. Drop into the conjunctival sac, and press the inner corner of the lacrimal sac with your fingers for 3 to 5 minutes.

1. Patients with bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease. 2. Sinus bradycardia, Ⅱ or Ⅲ degree atrioventricular block, obvious heart failure, cardiogenic shock. 3. Patients who are allergic to this product.

1. Combination with epinephrine may cause pupil dilation. 2. Patients who are taking catecholamine-depleting drugs (such as reserpine) should be closely observed when using this product, as it may cause hypotension and significant bradycardia. 3. It is not recommended to use two local beta-blockers at the same time. This product should be used with caution in patients who are taking oral beta-blockers. 4. This product should be used with caution in combination with calcium channel antagonists, as it may cause atrioventricular conduction block, left ventricular failure and hypotension. For patients with impaired cardiac function, the two drugs should be avoided in combination. 5. This product can further prolong atrioventricular conduction time when used in combination with digitalis and calcium channel antagonists. 6. Phenothiazines can increase the antihypertensive effect of beta-blockers because they can inhibit each other's metabolic pathways.

Keep away from light and store in a sealed container.

API